Cargando…
Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257229/ https://www.ncbi.nlm.nih.gov/pubmed/35812304 http://dx.doi.org/10.1016/j.reuma.2022.06.002 |
| _version_ | 1784741298343772160 |
|---|---|
| author | Morell-Hita, Jose Luis Rigual-Bobillo, Juan A. Macía-Villa, Cristina C. |
| author_facet | Morell-Hita, Jose Luis Rigual-Bobillo, Juan A. Macía-Villa, Cristina C. |
| author_sort | Morell-Hita, Jose Luis |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9257229 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92572292022-07-06 Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients Morell-Hita, Jose Luis Rigual-Bobillo, Juan A. Macía-Villa, Cristina C. Reumatol Clin Letter to the Editor Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2022-12 2022-07-06 /pmc/articles/PMC9257229/ /pubmed/35812304 http://dx.doi.org/10.1016/j.reuma.2022.06.002 Text en © 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Morell-Hita, Jose Luis Rigual-Bobillo, Juan A. Macía-Villa, Cristina C. Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients |
| title | Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients |
| title_full | Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients |
| title_fullStr | Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients |
| title_full_unstemmed | Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients |
| title_short | Post-COVID-19 interstitial lung disease: A new treatment challenge in rheumatoid arthritis patients |
| title_sort | post-covid-19 interstitial lung disease: a new treatment challenge in rheumatoid arthritis patients |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257229/ https://www.ncbi.nlm.nih.gov/pubmed/35812304 http://dx.doi.org/10.1016/j.reuma.2022.06.002 |
| work_keys_str_mv | AT morellhitajoseluis postcovid19interstitiallungdiseaseanewtreatmentchallengeinrheumatoidarthritispatients AT rigualbobillojuana postcovid19interstitiallungdiseaseanewtreatmentchallengeinrheumatoidarthritispatients AT maciavillacristinac postcovid19interstitiallungdiseaseanewtreatmentchallengeinrheumatoidarthritispatients |